BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 21119110)

  • 1. Blockade of osteopontin reduces alloreactive CD8+ T cell-mediated graft-versus-host disease.
    Zhao F; Zhang Y; Wang H; Jin M; He S; Shi Y; Guo Y; Zhang Y
    Blood; 2011 Feb; 117(5):1723-33. PubMed ID: 21119110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteopontin attenuates acute gastrointestinal graft-versus-host disease by preventing apoptosis of intestinal epithelial cells.
    Kawakami K; Minami N; Matsuura M; Iida T; Toyonaga T; Nagaishi K; Arimura Y; Fujimiya M; Uede T; Nakase H
    Biochem Biophys Res Commun; 2017 Apr; 485(2):468-475. PubMed ID: 28192120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of stem cell transcriptional programs normally expressed in embryonic and neural stem cells in alloreactive CD8+ T cells mediating graft-versus-host disease.
    Kato K; Cui S; Kuick R; Mineishi S; Hexner E; Ferrara JL; Emerson SG; Zhang Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):751-71. PubMed ID: 20116439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
    Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
    J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease.
    Zhang Y; Joe G; Hexner E; Zhu J; Emerson SG
    J Immunol; 2005 Mar; 174(5):3051-8. PubMed ID: 15728519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody.
    He S; Cao Q; Qiu Y; Mi J; Zhang JZ; Jin M; Ge H; Emerson SG; Zhang Y; Zhang Y
    J Immunol; 2008 Dec; 181(11):7581-92. PubMed ID: 19017947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease.
    Zhang Y; Sandy AR; Wang J; Radojcic V; Shan GT; Tran IT; Friedman A; Kato K; He S; Cui S; Hexner E; Frank DM; Emerson SG; Pear WS; Maillard I
    Blood; 2011 Jan; 117(1):299-308. PubMed ID: 20870902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice.
    Wu Y; Heinrichs J; Bastian D; Fu J; Nguyen H; Schutt S; Liu Y; Jin J; Liu C; Li QJ; Xia C; Yu XZ
    Blood; 2015 Sep; 126(11):1314-23. PubMed ID: 26138686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM).
    Taylor PA; Panoskaltsis-Mortari A; Freeman GJ; Sharpe AH; Noelle RJ; Rudensky AY; Mak TW; Serody JS; Blazar BR
    Blood; 2005 Apr; 105(8):3372-80. PubMed ID: 15618467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells.
    Yang YG; Qi J; Wang MG; Sykes M
    Blood; 2002 Jun; 99(11):4207-15. PubMed ID: 12010827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.
    Koestner W; Hapke M; Herbst J; Klein C; Welte K; Fruehauf J; Flatley A; Vignali DA; Hardtke-Wolenski M; Jaeckel E; Blazar BR; Sauer MG
    Blood; 2011 Jan; 117(3):1030-41. PubMed ID: 21063028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD103 deficiency prevents graft-versus-host disease but spares graft-versus-tumor effects mediated by alloreactive CD8 T cells.
    Liu K; Anthony BA; Yearsly MM; Hamadani M; Gaughan A; Wang JJ; Devine SM; Hadley GA
    PLoS One; 2011; 6(7):e21968. PubMed ID: 21779359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transplantation of Graft Anti-Host Cytotoxic T Lymphocytes Along with Allogeneic Bone Marrow Skips Macrophage-Induced Graft-Versus-Host Disease.
    Yoshida R; Yamana H; Hayashi M; Yasuda E; Shibayama Y; Hirose Y; Tanigawa N; Uchiyama K; Kubota T
    J Interferon Cytokine Res; 2021 Sep; 41(9):310-318. PubMed ID: 34543129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flt-3L Expansion of Recipient CD8α
    Markey KA; Kuns RD; Browne DJ; Gartlan KH; Robb RJ; Martins JP; Henden AS; Minnie SA; Cheong M; Koyama M; Smyth MJ; Steptoe RJ; Belz GT; Brocker T; Degli-Esposti MA; Lane SW; Hill GR
    Clin Cancer Res; 2018 Apr; 24(7):1604-1616. PubMed ID: 29367429
    [No Abstract]   [Full Text] [Related]  

  • 16. Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.
    Lu SX; Kappel LW; Charbonneau-Allard AM; Atallah R; Holland AM; Turbide C; Hubbard VM; Rotolo JA; Smith M; Suh D; King C; Rao UK; Yim N; Bautista JL; Jenq RR; Penack O; Na IK; Liu C; Murphy G; Alpdogan O; Blumberg RS; Macian F; Holmes KV; Beauchemin N; van den Brink MR
    PLoS One; 2011; 6(7):e21611. PubMed ID: 21760897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice.
    Yang YG; Sergio JJ; Pearson DA; Szot GL; Shimizu A; Sykes M
    Blood; 1997 Dec; 90(11):4651-60. PubMed ID: 9373279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graft-versus-host disease is enhanced by selective CD73 blockade in mice.
    Wang L; Fan J; Chen S; Zhang Y; Curiel TJ; Zhang B
    PLoS One; 2013; 8(3):e58397. PubMed ID: 23520507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor APCs are required for maximal GVHD but not for GVL.
    Matte CC; Liu J; Cormier J; Anderson BE; Athanasiadis I; Jain D; McNiff J; Shlomchik WD
    Nat Med; 2004 Sep; 10(9):987-92. PubMed ID: 15286785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.